Advertisement

Procedures in the Diagnosis and Treatment of Skin Cancer

  • Sarah Yagerman
  • Mary L. Stevenson
Chapter

Abstract

Skin cancer is the most common type of cancer in the United States and constitutes a health burden to the population. Comprised predominately of basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma, skin cancer accounts for nearly 20,000 deaths annually. Early diagnosis and treatment of skin cancer are critical in limiting morbidity and mortality. Diagnosis is generally made based on close examination and biopsy of suspicious lesions. Appropriate treatment depends on the specific histopathologic diagnosis as well as other considerations including area and size of the lesion and comorbidities of the patient. Treatment modalities include superficial therapies, such as cryotherapy or topical treatment, electrodessication and curettage, and surgical therapies including standard excision and Mohs micrographic surgery. Additionally, for more advanced disease, treatment may require a multidisciplinary approach, often with involvement of medical and radiation oncologists, and may include the use of systemic agents or radiation therapy.

Keywords

Biopsy Excision Melanoma Atypical nevi Non-melanoma skin cancer Keratinocyte carcinoma Basal cell carcinoma Cutaneous squamous cell carcinoma Mohs micrographic surgery 

Bibliography

  1. 1.
    Robinson JK. Sun exposure, sun protection, and vitamin D. JAMA. 2005;294(12):1541–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections – United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591–6.PubMedPubMedCentralGoogle Scholar
  4. 4.
    American Cancer Society. Cancer facts and figures 2016 [Internet]. Cited 19 Nov 2016. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
  5. 5.
    Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Stevenson ML, Glazer AM, Cohen DE, Rigel DS, Rieder EA. Frequency of total body skin examinations among US dermatologists. J Am Acad Dermatol. 2017;76(2):343–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Russak JE, Rigel DS. Risk factors for the development of primary cutaneous melanoma. Dermatol Clin. 2012;30(3):363–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, et al. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013;20(4):248–54.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Karimkhani C, Boyers LN, Dellavalle RP, Weinstock MA. It’s time for “keratinocyte carcinoma” to replace the term “nonmelanoma skin cancer”. J Am Acad Dermatol. 2015;72(1):186–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. JAMA Dermatol. 2015;151(9):976–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang W-T, Gelfand JM, Whalen FM, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Stevenson ML, Kim R, Meehan SA, Pavlick AC, Carucci JA. Metastatic cutaneous squamous cell carcinoma: the importance of T2 stratification and hematologic malignancy in prognostication. Dermatol Surg. 2016;42(8):932–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012.Google Scholar
  18. 18.
    Alguire PC, Mathes BM. Skin biopsy techniques for the internist. J Gen Intern Med. 1998;13(1):46–54.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Miedema J, Zedek DC, Rayala BZ, Bain EE. 9 tips to help prevent derm biopsy mistakes. J Fam Pract. 2014;63(10):559–64.PubMedGoogle Scholar
  20. 20.
    Stratman EJ, Elston DM, Miller SJ. Skin biopsy: identifying and overcoming errors in the skin biopsy pathway. J Am Acad Dermatol. 2016;74(1):19–25. quiz 25CrossRefPubMedGoogle Scholar
  21. 21.
    Steinsapir KD, Woodward JA. Chlorhexidine keratitis: safety of chlorhexidine as a facial antiseptic. Dermatol Surg. 2017;43(1):1–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315–28.CrossRefPubMedGoogle Scholar
  23. 23.
    Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol. 2006;54(6):1039–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Goldman G. The current status of curettage and electrodesiccation. Dermatol Clin. 2002;20(3):569–78. ixCrossRefPubMedGoogle Scholar
  25. 25.
    Kauvar ANB, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(11):1214–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Zitelli JA. TIPS for a better ellipse. J Am Acad Dermatol. 1990;22(1):101–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135(10):1177–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, et al. Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(5):574–97.CrossRefPubMedGoogle Scholar
  29. 29.
    Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123(3):340–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.CrossRefPubMedGoogle Scholar
  32. 32.
    Patel TN, Patel SB, Franca K, Chacon AH, Nouri K. Mohs micrographic surgery: history, technique, and advancements. Skinmed. 2014;12(5):289–92.PubMedGoogle Scholar
  33. 33.
    Force AHT, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50.CrossRefGoogle Scholar
  34. 34.
    Leslie DF, Greenway HT. Mohs micrographic surgery for skin cancer. Australas J Dermatol. 1991;32(3):159–64.CrossRefPubMedGoogle Scholar
  35. 35.
    Nguyen TH, Ho DQ-D. Nonmelanoma skin cancer. Curr Treat Options Oncol. 2002;3(3):193–203.CrossRefPubMedGoogle Scholar
  36. 36.
    Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67(6):1235–41.CrossRefPubMedGoogle Scholar
  37. 37.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Hernández-Machin B, Borrego L, Gil-García M, Hernández BH. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol. 2007;46(5):453–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Wilder RB, Kittelson JM, Shimm DS. Basal cell carcinoma treated with radiation therapy. Cancer. 1991;68(10):2134–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Wilder RB, Shimm DS, Kittelson JM, Rogoff EE, Cassady JR. Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol. 1991;127(11):1668–72.CrossRefPubMedGoogle Scholar
  41. 41.
    Childers BJ, Goldwyn RM, Ramos D, Chaffey J, Harris JR. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg. 1994;93(6):1169–73.CrossRefPubMedGoogle Scholar
  42. 42.
    Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer. 2007;109(6):1053–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Mendenhall WM, Ferlito A, Takes RP, Bradford CR, Corry J, Fagan JJ, et al. Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol. 2012;48(10):918–22.CrossRefPubMedGoogle Scholar
  44. 44.
    Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35(4):574–85.CrossRefPubMedGoogle Scholar
  45. 45.
    Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS. Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg. 2008 Dec;34(12):1642–51.PubMedGoogle Scholar
  46. 46.
    Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Chang J, Zhu GA, Cheung C, Li S, Kim J, Chang ALS. Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities. JAMA Dermatol. 2017;153(4):285–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832–40.CrossRefPubMedGoogle Scholar
  49. 49.
    Sinclair RD, Dawber RP. Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Australas J Dermatol. 1995;36(3):133–42.CrossRefPubMedGoogle Scholar
  50. 50.
    Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PSJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105.CrossRefPubMedGoogle Scholar
  51. 51.
    Quirk C, Gebauer K, De’Ambrosis B, Slade HB, Meng T-C. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6):318–24.PubMedGoogle Scholar
  52. 52.
    Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025–32.CrossRefPubMedGoogle Scholar
  53. 53.
    Arits AHMM, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJM, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–54.CrossRefPubMedGoogle Scholar
  54. 54.
    Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg. 2011;37(10):1394–411.CrossRefPubMedGoogle Scholar
  55. 55.
    Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22(3):189–96.CrossRefPubMedGoogle Scholar
  56. 56.
    Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 2014;24(1):23–7.PubMedGoogle Scholar
  57. 57.
    Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4(1):11–31.CrossRefGoogle Scholar
  58. 58.
    U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. [Internet]. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. 2013. Cited 18 Nov 2016. Available from: http://www.cdc.gov/uscs.
  59. 59.
    National Cancer Institute. Cancer Stat Facts: melanoma of the Skin [Internet]. Surveillance, Epidemiology, and End Results Program (SEER). Cited 27 Feb 2017. Available from: https://seer.cancer.gov/statfacts/html/melan.htmlSurv
  60. 60.
    Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17–25.e1.PubMedGoogle Scholar
  61. 61.
    Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J Dermatol. 2009;161(6):1270–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Haliasos EC, Kerner M, Jaimes N, Zalaudek I, Malvehy J, Hofmann-Wellenhof R, et al. Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. Pediatr Dermatol. 2013;30(3):281–93.CrossRefPubMedGoogle Scholar
  63. 63.
    Malvehy J, Puig S. Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin Dermatol. 2002;20(3):297–304.CrossRefPubMedGoogle Scholar
  64. 64.
    Stell VH, Norton HJ, Smith KS, Salo JC, White RL. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol. 2007;14(2):893–8.CrossRefPubMedGoogle Scholar
  65. 65.
    McCarthy SW, Scolyer RA. Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. Ochsner J. 2010;10(2):66–74.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, et al. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014;12(5):621–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014;170(1):20–30.CrossRefPubMedGoogle Scholar
  68. 68.
    Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol. 2010;146(3):234–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. Am Acad Dermatol J Am Acad Dermatol. 2011;65(5):1032–47.CrossRefPubMedGoogle Scholar
  70. 70.
    Gauwerky KJ, Kunte C, Geimer T, Baumert J, Flaig MJ, Ruzicka T, et al. The outcome of patients with melanoma is not associated with the time point of lymphatic mapping with respect to excisional biopsy of the primary tumor. Dermatology (Basel). 2010;220(4):355–62.CrossRefGoogle Scholar
  71. 71.
    Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: pigmented lesion subcommittee consensus statement. JAMA Dermatol. 2015;151(2):212–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer. 2000;88(3):589–95.CrossRefPubMedGoogle Scholar
  73. 73.
    Caldarella A, Fancelli L, Manneschi G, Chiarugi A, Nardini P, Crocetti E. How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis. J Cancer Res Clin Oncol. 2016;142(1):73–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Oude Ophuis CMC, Louwman MWJ, Grünhagen DJ, Verhoef K, van Akkooi ACJ. Implementation of the 7th edition AJCC staging system: effects on staging and survival for pT1 melanoma. A Dutch population based study. Int J Cancer. 2017;140(8):1802–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Ivan D, Prieto VG. An update on reporting histopathologic prognostic factors in melanoma. Arch Pathol Lab Med. 2011;135(7):825–9.PubMedGoogle Scholar
  76. 76.
    Burton AL, Egger ME, Gilbert JE, Stromberg AJ, Hagendoorn L, Martin RCG, et al. Assessment of mitotic rate reporting in melanoma. Am J Surg. 2012;204(6):969–74. discussion 974CrossRefPubMedGoogle Scholar
  77. 77.
    Feng Z, Zhang Z, Wu X-C. Lifetime risks of cutaneous melanoma by histological subtype and race/ethnicity in the United States. J La State Med Soc. 2013;165(4):201–8.PubMedGoogle Scholar
  78. 78.
    Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol. 2012;66(3):438–44.CrossRefPubMedGoogle Scholar
  79. 79.
    Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58(1):142–8.CrossRefPubMedGoogle Scholar
  80. 80.
    MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, et al. The association between excision margins and local recurrence in 11,290 thin (T1) primary cutaneous melanomas: a case-control study. Ann Surg Oncol. 2016;23(4):1082–9.CrossRefPubMedGoogle Scholar
  81. 81.
    Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218(3):262–7. discussion 267CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3 Pt 1):422–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma. Transactions of the meeting of the American Surgical Association. 2005;123(&NA):10–20.CrossRefGoogle Scholar
  84. 84.
    Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160–5.CrossRefPubMedGoogle Scholar
  85. 85.
    Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9(7):637–45.CrossRefPubMedGoogle Scholar
  86. 86.
    Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13(3):302–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Ronald O. Perelman Department of DermatologyNYU Langone Medical CenterNew YorkUSA

Personalised recommendations